Results for fibrin dominant clots: (A) time to recanalize <i>in vitro</i> model; (B) relative clot reduction; (C) RBC release; (D) relative clot degradation rate. by Sandra Thalerová (11434762)

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Summary of the screened symptoms at baseline (t0) for completers (n = 160). by Anton Kurapov (11346019)

Subjects:

Summary of the program evaluation. by Anton Kurapov (11346019)

Subjects:

Changes in continuous sleep measures from pre (t1) to post (t2) intervention. by Anton Kurapov (11346019)

Subjects:

Overview over the contents of the app program divided by level [28]. by Anton Kurapov (11346019)

Subjects:

Sociodemographic information, participant flow, engagement, and compliance. by Anton Kurapov (11346019)

Subjects:

Changes in mental health symptoms after the sleep intervention (n = 160 completers). by Anton Kurapov (11346019)

Subjects:

‘Sleep2Ukraine’ study design. by Anton Kurapov (11346019)

Subjects:

Density differences between pre- and post-measurements for program completers (N = 160). by Anton Kurapov (11346019)

Subjects:

Reduction of L O-ag production and antigenic shift to O2-antigen in by Fermin E. Guerra (6084545)

“…<p><b><i>S.</i> Paratyphi A decreases IgM binding. (</b>A) and (B) Restored <i>S.…”

Atg14 deficiency in Tregs induces a type-I-dominant lymphoproliferative disease and cell-intrinsic reductions in eTregs. by Erienne G. Norton (9612079)

Food intake in groups A, B and C. by Sohail Afzal (10850709)

“…EPG values were used to determine the fecal egg count reduction (FECR). Statistically, there was a significant decrease in EPG values from days 0–14. …”

Interventions for Psychological Stress in Pregnant African American Women: A Scoping Review by Taleah A. Frazier (22423294)

Subjects:

Patient demographics. by Katrine Carlsen (5477300)

Subjects:

Association across weeks to treatment for three genera. by Katrine Carlsen (5477300)

Subjects:

Genera associated with FC, symptom score or week to treatment. by Katrine Carlsen (5477300)

Subjects:

Changes in alpha diversity in the weeks before anti-TNF-a treatment. by Katrine Carlsen (5477300)

Subjects:

Family clades associating with week to treatment, symptom score or FC. by Katrine Carlsen (5477300)

Subjects:

Alpha diversity measures across all 727 samples. by Katrine Carlsen (5477300)

Subjects: